• <table id="gigg0"></table>
  • west china medical publishers
    Author
    • Title
    • Author
    • Keyword
    • Abstract
    Advance search
    Advance search

    Search

    find Author "管小俊" 3 results
    • Intrapulmonary Delivery of Bone Marrow Mesenchymal Stem Cells Can Attenuate Chroic Inflammation of Emphysematous Rats

      Objective Bone marrow mesenchymal stem cells (MSCs) have been suggested to play an important role in the treatment of a variety of pulmonary diseases. The present study was aimed at evaluating the therapeutical effect of MSCs transplantation on emphysematous rats,and explore its influence in local and systemic inflammation. Methods Emphysema rat model was established by cigarette smoking. MSCs were transfected with lentivirus vector carrying green fluorecent protein (GFP) and the transfected MSCs in lung of smoke rats were detected by imaging system for small animals. Thirty-six SD rats were randomly divided into a control group,an emphysema group,and a MSCs transplantation group. The total and differential cell counts in bronchoalveolar lavage fluid (BALF) were measured. TNF-α and IL-1β levels in BALF and serum were measured by ELISA. Malonaldehyde (MDA) level in lung tissue was detected by chromatometry. Emphysema changes were evaluated by mean linear intercept (MLI) of lung under light microscope by HE staining. Results The transfected MSC in different lung lobes were found to be alive at four weeks after intrapulmonary delivery. Compared with the emphysema group,the total cell count in BALF,TNF-α and IL-1β levels in BALF and serum,MDA level in lung tissue and MLI were significantly reduced intheMSCs transplantation group(Plt;0.01). Conclusions Transplantation of MSCs can mediate down-regulation of TNF-α and IL-1β in BALF and serum,attenuate inflammation,oxidative stress and emphysema change of lung,suggesting that MSCs have significant therapeutic effects on emphysema.

      Release date:2016-08-30 11:58 Export PDF Favorites Scan
    • 免疫檢查點抑制劑治療合并乙型肝炎或丙型肝炎的晚期非小細胞肺癌的安全性及療效分析

      目的 探討合并乙型肝炎或丙型肝炎的晚期非小細胞肺癌(non-small cell lung cancer,NSCLC)免疫檢查點抑制劑(immune checkpoint inhibitors,ICIs)治療的安全性和療效。方法 回顧性分析5例合并乙型肝炎或丙型肝炎的NSCLC,觀察谷丙轉氨酶(alanine aminotransferase,ALT)水平、病毒載量和總生存期。結果 1例活動性乙型肝炎和1例活動性丙型肝炎啟動ICIs治療時,ALT升高,加用抗病毒和保肝治療,ALT即恢復正常。2例活動性和1例慢性乙型肝炎ICIs治療,ALT持續正常水平。2例完全緩解,3例部分緩解,目前死亡2例,最長總生存期35.7個月,其余3例仍在隨訪中。結論 乙型肝炎或丙型肝炎不影響ICIs在NSCLC中的治療地位,包括在部分NSCLC的一線治療,全程監測肝功能和病毒拷貝數,推薦聯合抗病毒治療(特別對合并乙型肝炎),個體化調整抗病毒時機及療程。

      Release date:2023-01-18 06:43 Export PDF Favorites Scan
    • 鸚鵡熱衣原體肺炎的臨床診療特點

      目的 探討鸚鵡熱衣原體肺炎的臨床診療特點。方法 收集2020年9月—2021年12月由蘇州大學附屬第一醫院和附屬獨墅湖醫院呼吸與危重癥醫學科收治的12例鸚鵡熱衣原體肺炎患者的臨床資料,進行總結分析。結果 12例患者均以高熱、咳嗽為主要表現起病,9例患者接觸過鸚鵡,3例接觸過活禽。12例患者淋巴細胞計數均不同程度降低,2例患者白細胞、中性粒細胞和降鈣素原明顯升高;C反應蛋白、紅細胞沉降率和D-二聚體均明顯升高,而白蛋白水平明顯降低,4例患者出現了低鉀血癥。1例重癥患者合并了呼吸衰竭、心力衰竭、肝衰竭、腎衰竭及輕度精神癥狀。胸部CT均表現為單一肺葉或多肺葉炎癥滲出和實變,5例合并有少量胸腔積液。患者初始經驗性治療效果均不理想,支氣管肺泡灌洗液宏基因組二代測序技術檢測診斷鸚鵡熱衣原體肺炎后,及時調整以四環素類藥物和(或)喹諾酮類抗生素為基礎的治療方案后病情均好轉出院。結論鸚鵡熱衣原體肺炎臨床相對少見,臨床表現以及常規檢查很難與其他社區獲得性肺炎鑒別,易導致誤診和漏診,應引起臨床醫生的重視,宏基因組二代測序技術在鸚鵡熱衣原體肺炎診療方面具有重要指導意義,值得臨床應用和推廣。

      Release date: Export PDF Favorites Scan
    1 pages Previous 1 Next

    Format

    Content

  • <table id="gigg0"></table>
  • 松坂南